Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
US FDA approves Evolus' anti-wrinkle gels
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharply, possibly due to market unpredictability and sector instability. Evolus' ambitious revenue targets and profitability projections face skepticism, but strong product performance and brand loyalty offer optimism.
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher
Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago.
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Rui Avelar - Chief Medical Officer and Head of R&D Conference Call Participants Jack Padovano - Stifel Navann Ty - BNP Serge Belanger - Needham & Company Operator Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago.
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Medical aesthetics company Evolus notched its first-ever profits late Wednesday — two quarters ahead of expectations.
